New LC-HRMS Method Accurately Identifies Impurities in Thymalfasin Peptide Drug
Background
Thymalfasin, a synthetic peptide drug, is widely used as an immunomodulator to enhance immune function, particularly in conditions like hepatitis B and certain cancers. The presence of structurally related peptide impurities can significantly impact the drug's safety, efficacy, and stability, posing potential risks to patients. Existing analytical methods often lack the necessary sensitivity and specificity to comprehensively identify and quantify these complex, low-level impurities in thymalfasin products.
Results
The developed LC-HRMS method successfully identified and characterized 7 novel structurally related peptide impurities in thymalfasin, which were previously undetected by conventional methods. The method demonstrated exceptional sensitivity, with a limit of detection (LOD) as low as 0.005% for major impurities and a limit of quantification (LOQ) of 0.015%. In commercial batches, total impurity levels ranged from 0.08% to 0.45%, with one specific impurity (des-acetyl thymalfasin) consistently found at 0.12% ± 0.02% across multiple samples. > The LC-HRMS method achieved a 3.2-fold increase in sensitivity and a 95% improvement in impurity identification rate compared to standard HPLC-UV methods, providing unprecedented detail into thymalfasin's impurity profile. The method also showed excellent linearity (R² > 0.999) and precision (RSD < 1.8%) for all quantified impurities, ensuring reliable and accurate results.
Why It Matters
This study provides a robust and highly sensitive analytical tool for the comprehensive quality control of thymalfasin, significantly enhancing the ability to detect and quantify potentially harmful impurities. The identification of previously unknown impurities is crucial for ensuring the safety and consistent efficacy of this important immunomodulatory drug. This advanced LC-HRMS method could become a new gold standard for regulatory testing and quality assurance in the pharmaceutical industry for thymalfasin and potentially other complex peptide therapeutics, leading to higher quality drug products and improved patient outcomes. Future steps include adapting this methodology for other peptide drugs and potentially incorporating it into pharmacopoeial monographs.